Form 4: Larimar Therapeutics CDO Acquires Equity Awards

Larimar Therapeutics' Chief Development Officer, Gopi Shankar, acquired 25,637 restricted stock units and 153,822 stock options.

Summary

• Gopi Shankar, Chief Development Officer of Larimar Therapeutics, Inc. (LRMR), acquired 25,637 shares of common stock in the form of restricted stock units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement, with an acquisition price of $0.00 per share.
• Shankar also acquired 153,822 stock options on January 26, 2026, with an exercise price of $3.60 per share and an acquisition price of $0.00.
• The stock options vest 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, contingent on continued service.
• Following these transactions, Shankar beneficially owns 76,443 shares of common stock directly and 153,822 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally viewed positively as it aligns the executive's interests with those of shareholders, incentivizing long-term performance and retention. This is a routine compensation disclosure.

Positives

• The grant of equity awards to the Chief Development Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The acquisition of a significant number of stock options and restricted stock units demonstrates continued commitment from a key executive.

Future Outlook

The vesting schedule for the stock options, extending over three years, indicates an expectation of continued service from the Chief Development Officer, aligning future performance with equity incentives.

Industry Context

Equity grants, including restricted stock units and stock options, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and motivate key talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The structure of equity compensation, involving both RSUs and stock options with multi-year vesting schedules, is a common practice across the biotechnology sector for executive incentives.
• Without specific details on comparable company compensation plans or performance metrics, a direct quantitative comparison to industry benchmarks for this specific grant is not possible based solely on this filing.

Related Party Transactions

• The acquisition of restricted stock units and stock options by Gopi Shankar, the Chief Development Officer, represents an equity grant from Larimar Therapeutics to an executive officer, which is a related party transaction as part of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Development Officer's interests with shareholder value creation, potentially leading to improved long-term performance. However, the issuance of new shares upon RSU settlement and option exercise could lead to minor dilution.
• Employees: This compensation structure may serve as a benchmark or incentive for other key employees, reinforcing a performance-based culture.

Next Steps

• Gopi Shankar's continued service with Larimar Therapeutics is required for the vesting of the acquired stock options and settlement of RSUs.

Key Dates

Keywords

Larimar Therapeutics, LRMR, Gopi Shankar, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Chief Development Officer